Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...